What is the recommended oral diltiazem tablet dosing after a paroxysmal supraventricular tachycardia (PSVT) in a hemodynamically stable patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Oral Diltiazem Dosing After PSVT

For ongoing management after PSVT, oral diltiazem is recommended at doses ranging from 120-360 mg daily, typically starting at 120-180 mg/day divided into multiple doses, with the option to titrate upward based on response. 1, 2

Guideline-Based Recommendations

The 2015 ACC/AHA/HRS guidelines provide a Class I recommendation for oral verapamil or diltiazem for ongoing management in patients with AVNRT (the most common form of PSVT) who are not candidates for or prefer not to undergo catheter ablation. 1, 2 This represents the highest level of recommendation, indicating these agents are proven effective pharmacological alternatives to ablation.

Specific Dosing Considerations

Starting and Maintenance Doses

Based on FDA labeling and clinical studies:

  • Initial dosing: 30-60 mg four times daily (120-240 mg/day total) 3
  • Dose range: Studies demonstrate efficacy from 120 mg/day up to 360 mg/day 3, 4, 5
  • Pharmacokinetics: Peak plasma levels occur 2-4 hours after administration, with therapeutic levels between 50-200 ng/mL 3

Dose-Response Relationship

The FDA labeling indicates non-linear pharmacokinetics when increasing doses:

  • 120 mg to 240 mg daily: 2.3-fold increase in drug exposure
  • 240 mg to 360 mg daily: 1.8-fold increase in drug exposure 3

This means you get diminishing returns with higher doses, so careful titration is warranted.

Clinical Evidence for Efficacy

Research demonstrates that oral diltiazem prevents PSVT recurrence in the majority of patients:

  • In one study, oral diltiazem (270 mg in divided doses) prevented induction of sustained SVT in 78% of patients (28/36) 5
  • Another study using 90 mg every 8 hours (270 mg/day total) prevented sustained tachycardia induction in 63% of patients (10/16) 4
  • Long-term follow-up showed patients without inducible sustained SVT on diltiazem remained largely asymptomatic 4, 5

Critical Safety Considerations

Absolute contraindications and cautions:

  • Avoid in systolic heart failure - diltiazem can worsen heart failure despite minimal negative inotropic effects in patients with preserved function 1, 2
  • Monitor for bradyarrhythmias and hypotension when initiating therapy 1, 2
  • Avoid in pre-excited atrial fibrillation (WPW syndrome with AF) - can cause hemodynamic collapse 1, 2
  • Hepatic impairment: 69% increase in drug exposure; dose reduction needed 3
  • Sick sinus syndrome: Can prolong sinus cycle length up to 50% 3

Practical Algorithm for Dosing

  1. Confirm diagnosis and ensure no contraindications (heart failure, pre-excitation, sick sinus syndrome)
  2. Start with 120-180 mg/day divided into 3-4 doses (e.g., 60 mg TID or 30-60 mg QID)
  3. Monitor blood pressure, heart rate, and PR interval on ECG
  4. Titrate upward if breakthrough symptoms occur, up to maximum 360 mg/day
  5. Consider chronic dosing of 240 mg/day as this has been well-studied without producing abnormal PR prolongation 3

Alternative: Combination Therapy

For acute termination (not ongoing management), studies show single-dose combination of diltiazem 120 mg plus propranolol 160 mg successfully terminated PSVT in 93% of patients (14/15) within an average of 27 minutes. 6 However, this caused transient second-degree AV block in 2 patients, highlighting the need for caution with combination therapy.

Key Clinical Pearls

  • Diltiazem works primarily by increasing AV nodal refractoriness, making it particularly effective for AVNRT and orthodromic AVRT 4, 5
  • Effects last approximately 8 hours with standard formulations 4
  • Chronic administration (up to 240 mg/day) produces only small increases in PR interval without abnormal prolongation in most patients 3
  • First-line definitive therapy remains catheter ablation (94-98% success rate), with diltiazem reserved for patients who decline or are not candidates for ablation 7

budget:token_budget Tokens used this turn: 1347 Total tokens used: 1347 Remaining budget: 198653

References

5
Research

Effects of oral diltiazem in paroxysmal supraventricular tachycardia.

The American journal of cardiology, 1983

Related Questions

Which drugs can precipitate paroxysmal supraventricular tachycardia (PSVT) and what are the recommended acute and long‑term treatment options?
In a 50-year-old patient with paroxysmal supraventricular tachycardia at 180 bpm, what should be done?
What is the appropriate dose of diltiazem controlled-release (CD) for treating supraventricular tachycardia (SVT)?
What is the appropriate acute management for a patient presenting with a heart rate of 190 bpm and brief chest discomfort that diminishes after the tachycardia resolves?
What is the appropriate management of paroxysmal supraventricular tachycardia (PSVT) in a patient who is post‑percutaneous transluminal coronary angioplasty (PTCA) with stent placement and on dual antiplatelet therapy?
Does a transdermal diclofenac patch applied over a painful joint deliver therapeutic concentrations into the joint space?
What is medication‑overuse headache and how is it managed?
What is the best topical cream for treating facial acne in a healthy 23‑year‑old woman?
Is Candida tropicalis a virulent pathogen?
In a patient with seronegative arthritis on sulfasalazine who presents with severe headache and abdominal pain, what are the differential diagnoses?
What are the differential diagnoses for a patient with recurrent anemia, recurrent hyponatremia, and chronic osteomyelitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.